5 Amino 1mq vs Nmn
Which Is Right for You? Complete Comparison (2026)
5-Amino-1MQ vs NMN comparison — NNMT inhibitor (prevent NAD+ waste) vs NAD+ precursor (add more input).
5 Amino 1mq vs Nmn: At a Glance
- ✓Selective inhibitor of NNMT enzyme in fat cells
- ✓Reduces adipocyte size and lipid accumulation
- ✓Increases cellular NAD+ levels
- ✓Reversed high-fat-diet obesity in mice
- ✓Oral bioavailability — no injection needed
- ✓Direct biosynthetic precursor to NAD+
- ✓Converted to NAD+ by NMNAT enzymes in cells
- ✓Oral supplementation raises blood NAD+ levels in human studies
- ✓Reversed age-related metabolic dysfunction in mouse models
- ✓Available as oral supplement — no injection needed
Detailed Comparison
| Feature | 5 Amino 1mq | Nmn |
|---|---|---|
| Mechanism | NNMT inhibitor | NAD+ precursorBest |
| Dosing | 50-100 mg orally daily | 250-1000 mg orally daily |
| Administration | Oral | Oral |
| Half-life | Not well-characterized in humans | Rapidly converted to NAD+ after absorption |
| FDA Status | Not FDA-approved — research compound | Supplement (regulatory status debated by FDA) |
| Key Trial | Neelakantan H et al. Biochem Pharmacol 2018 — obesity reversal | Yoshino J et al. Cell Metab 2011 — pathophysiology of diet/age-induced diabetes |
| Side Effects | Limited human data; GI discomfort reported anecdotally | Generally well-tolerated; GI discomfort at high doses |
Which Should You Choose?
5-Amino-1MQ (nnmt inhibitor) and NMN (Nicotinamide Mononucleotide) (nad+ precursor) serve different clinical roles despite both being in the Metabolic research compound space. 5-Amino-1MQ small molecule inhibitor of nicotinamide n-methyltransferase (nnmt) that reduces fat cell size and increases nad+ levels in adipose tissue. NMN (Nicotinamide Mononucleotide) direct biosynthetic precursor to nad+ that is converted by nmnat enzymes.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between 5 Amino 1mq and Nmn
Choosing between 5 Amino 1mq and Nmn depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between 5 Amino 1mq and Nmn is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
5 Amino 1mq vs Nmn: Frequently Asked Questions
5-Amino-1MQ is an NNMT inhibitor that blocks the enzyme that wastes NAD+ precursors — preventing cellular NAD+ depletion. NMN is a direct NAD+ precursor that adds more substrate to the NAD+ biosynthesis pathway. They target opposite ends of NAD+ metabolism: 5-Amino-1MQ reduces wasteful consumption while NMN increases production.
5-Amino-1MQ and NMN have complementary mechanisms and are frequently stacked. 5-Amino-1MQ blocks NNMT-mediated NAD+ wastage, while NMN provides additional substrate. A common protocol is 5-Amino-1MQ 50 mg daily + NMN 500 mg daily, taken together in the morning.
5-Amino-1MQ has documented fat loss effects in animal models via NNMT inhibition in adipose tissue. NNMT in fat cells creates a metabolically dormant state by depleting local SAM and reducing SIRT1 activity. Inhibiting NNMT restores adipocyte metabolism, increases fatty acid oxidation, and reduces adipogenesis. Human data are growing via clinical practitioner case reports.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track 5 Amino 1mq or Nmn in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.